Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)

Paget's Disease of Bone Clinical Trial

Official title:
A 6 Months, Open-Label Phase IV Study to Confirm the Safety and Efficacy of Single Intravenous Dose of 5 mg Zoledronic Acid for the Patients of Paget's Disease of Bone (PDB) in China

Status Completed

Clinical Trial Summary

The purpose of this study is to document the efficacy and safety profiles of single intravenous dose of 5 mg zoledronic acid for the Chinese patients of Paget's Disease of Bone (PDB).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00774020
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 4
Start date	October 30, 2008
Completion date	January 14, 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00747994` - Genetic Study of Families Affected by Paget's Disease of Bone	N/A
Completed	`NCT00480662` - A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)	Phase 3
Completed	`NCT00051636` - Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period	Phase 3
Completed	`NCT00306046` - 18F-Fluoride Positron Emission Tomography (PET) in Paget's Disease of Bone	N/A
Active, not recruiting	`NCT02802384` - Pathophysiology of Paget's Disease of Bone
Completed	`NCT00103740` - Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period	Phase 3